Advertisement


Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement



Jul
30
Today In Oncology
Frailty and Neurocognitive Decline Among Young Adult Childhood Cancer Survivors
Association of Baseline Fatigue With Survival and Adverse Events in Patients With Advanced Cancer
Study Explores Rates of Reconstruction for Women With Inflammatory Breast Cancer Undergoing Mastectomy
Clinical Trial Results Show an Increased Risk of Death Associated With Melphalan Flufenamide
Perioperative or Postoperative Oxaliplatin/S-1 vs Postoperative Oxaliplatin/Capecitabine for Locally Advanced Gastric Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside